Axsome Therapeutics, Inc. (LON:0HKF)

Market Cap	6.21B +26.1%
Revenue (ttm)	474.40M +65.5%
Net Income	-136.10M
EPS	-2.74
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	403
Average Volume	443
Open	162.50
Previous Close	162.35
Day's Range	158.42 - 162.50
52-Week Range	88.21 - 193.51
Beta	0.40
RSI	31.20
Earnings Date	Feb 23, 2026

About Axsome Therapeutics

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 925
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HKF

Financial Performance

In 2025, Axsome Therapeutics's revenue was $638.50 million, an increase of 65.55% compared to the previous year's $385.69 million. Losses were -$183.17 million, -36.22% less than in 2024.

Financial numbers in USD